2R-hydroxy-4-N-isopropylaminobutane | 175438-79-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2R-hydroxy-4-N-isopropylaminobutane
• 英文别名: 2R-Hydroxy-4-(N-isopropyl)aminobutane；(2R)-4-(propan-2-ylamino)butan-2-ol
• CAS: 175438-79-6
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: NGVGMMWXUKIWPX-SSDOTTSWSA-N

物化性质

• 沸点：
  195.7±23.0 °C(Predicted)
• 密度：
  0.868±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2R-hydroxy-4-N-isopropylaminobutane 在 三乙胺 、 三氯化磷 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 1-[(2R,4S,5R)-5-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-[[(2R,6R)-6-methyl-3-propan-2-yl-1,3,2-oxazaphosphinan-2-yl]oxy]oxolan-2-yl]-5-methylpyrimidine-2,4-dione
  参考文献：
  名称：

  亚磷酸酯三酯的非对映选择性合成

  摘要：

  已获得具有高非对映异构体过量的环状亚磷酰胺，无需色谱纯化。使用相对较大的酸性2-溴-4,5-二氰基咪唑作为催化剂，它们已以立体选择性方式转化为亚磷酸三酯。

  DOI：

  10.1016/0040-4039(95)02354-2
• 作为产物：
  描述：

  3R-hydroxy-N-iso-propyl-butyl butanoamide 在 盐酸 、 硼烷 作用下， 以 四氢呋喃 为溶剂， 生成 2R-hydroxy-4-N-isopropylaminobutane
  参考文献：
  名称：

  Preparation of chiral phosphorothioate oligomers

  摘要：

  揭示了含有对映异构富集的磷硫酸酯键的寡聚物制备的方法和中间体。

  公开号：

  US05734041A1

文献信息

• Preparation of phosphorothioate and boranophosphate oligomers
  申请人：Isis Pharmaceuticals, Inc.

  公开号：US06160109A1

  公开（公告）日：2000-12-12

  Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate and boranophosphate linkages are disclosed.

  揭示了含有对映异构富集的磷硫酸酯和硼磷酸酯键的寡聚物制备的方法和中间体。
• Preparation of chiral phosphorothioate oligomers
  申请人：McGill University

  公开号：US05734041A1

  公开（公告）日：1998-03-31

  Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate linkages are disclosed.

  揭示了含有对映异构富集的磷硫酸酯键的寡聚物制备的方法和中间体。
• Acetamide thienotriazolodiazepines and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US10881668B2

  公开（公告）日：2021-01-05

  The present invention provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits using the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.

  本发明提供了式(I)化合物及其药用组合物。式（I）化合物是溴基链和/或含溴基链蛋白质（如溴外末端（BET）蛋白质）的结合剂。还提供了使用本发明化合物和药物组合物的方法、用途和试剂盒，用于抑制溴基链和/或含溴基链蛋白的活性（如活性增加），治疗和/或预防受试者与溴基链或含溴基链蛋白相关的疾病（如增殖性疾病、心血管疾病、病毒感染、纤维化疾病、代谢性疾病、内分泌疾病和辐射中毒）。这些化合物、药物组合物和试剂盒还可用于男性避孕。
• PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS
  申请人：McGill University

  公开号：EP0904275B1

  公开（公告）日：2006-05-17
• SMALL MOLECULES FOR INDUCING SELECTIVE PROTEIN DEGRADATION AND USES THEREOF
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20200407371A1

  公开（公告）日：2020-12-31

  Provided herein are bifunctional compounds that bind a target protein (e.g., a selected protein) and/or induce ubiquitination for degradation of the target protein. In particular, provided are compounds that bind a bromodomain or bromodomain-containing protein (e.g., BET proteins) or histone methyltransferases (HMTs, e.g., enhancer of zeste homolog 1 (EZH1), or FKBP12) and can promote its degradation by recruiting it to the ubiquitin receptor RPN13 (e.g., RA190), for proteasomal degradation. Also provided are pharmaceutical compositions comprising the bifunctional compounds, methods of treating and/or preventing diseases (e.g., proliferative diseases, cancers, benign neoplasms, pathological angiogenesis, inflammatory diseases, and autoimmune diseases) and musculoskeletal diseases, and methods of inducing the degradation of a target (e.g., a target protein) by recruiting it to the ubiquitin receptor RPN13 of the proteasome in a subject by administering a compound or composition described herein.